Skip to main content
OpenTrials
Completed

NCT Number: NCT00464204

Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis

The rapidity and the quality of fluid resuscitation in patients with severe sepsis are important factors for the prevention of secondary multi-organ failure. Vascular filling may also have an impact on tolerability of enteral nutrition. The earliness and quantity of calories provided by enteral nutrition may have an impact on morbidity and mortality. This study will asses the effects of volume expansion on hemodynamics and tolerability of enteral nutrition in patients with severe sepsis. A Data Monitoring Committee will review regularly safety data of the study.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Hôpital Sud, Unité de Réanimation Médicale, Amiens, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Severe sepsis
  • Requirement for fluid resuscitation

Exclusion criteria

  • serum creatinine > 300µmol/L
  • Chronic renal failure
  • Anuria lasting more than 4 hours
  • Requirement for renal support

Treatment and study plan

6 % Hydroxyethylstarch 130/0.4 = "Voluven®"

Drug

Voluven® was administered intravenously. Voluven® rates were not to exceed 50 mL/kg/day on the first day and 25 mL/kg/day on the second to fourth days, according to patient needs.

Other names: Voluven®

0.9 % NaCl

Drug

NaCl 0.9 % was administered intravenously. NaCl 0.9% rates were not to exceed 50 mL/kg/day on the first day and 25 mL/kg/day from the second to the fourth day, according to patient needs.

Primary outcomes

  1. Amount of Study Drug Required to Achieve Initial Hemodynamic Stabilization

    Time frame: until hemodynamic stabilization (up to 48 hours)

    Initial hemodynamic stabilization (HDS) was defined as normalization of mean arterial pressure (MAP) and at least two of the three parameters central venous pressure (CVP), urine output and central venous oxygen saturation and maintaining this normalization over a period of four hours, with no increase in the infusion of vasopressors, or ionotropic therapy and with no more than 1 L of additional study drug administration within these four hours.

Secondary outcomes

  1. Time From Start of Fluid Resuscitation With Study Drug to the Initial Hemodynamic Stabilization

    Time frame: until hemodynamic stabilization (up to 48 hours)

    Time from start of fluid resuscitation with study drug to the initial hemodynamic stabilization

  2. Quantity of Study Drug in 4 Days

    Time frame: 4 days

    Total quantity of study drug infused over four consecutive days in the ICU

  3. Time From Start of Study Drug to Start of Enteral Nutrition in the Subgroup of Patients Who Received Enteral Nutrition

    Time frame: Until start of enteral nutrition (up to 48 hours)

    Time from start of fluid resuscitation with study drug to start of enteral nutrition.

  4. Time From Start of Fluid Resuscitation With Study Drug to Start of Enteral Nutrition After Hemodynamic Stabilization

    Time frame: up to 48 hours

    Administration of enteral nutrition before initial hemodynamic stabilization was ignored in this analysis.

  5. Total Amount of Enteral Calories During the First Seven Days of Enteral Nutrition

    Time frame: 7 days

    This amount will be calculated from start of enteral nutrition until 7 am of day 8

  6. Length of Stay in the Intensive Care Unit (ICU)

    Time frame: Until discharge from ICU (up to day 90)

    Length of stay was analysed in two approaches. First, it was calculated and analysed only for patients who did not die before end of study of the individual patient. As a sensitivity analysis, the analysis was carried out including patients who died with the maximum possible length of stay (i.e., the worst possible value).

  7. Length of Stay in the ICU

    Time frame: Until discharge from ICU (up to Day 90)

    Length of stay was analysed in two approaches. First, it was calculated and analysed only for patients who did not die before end of study of the individual patient. As a sensitivity analysis, the analysis was carried out including patients who died with the maximum possible length of stay (i.e., worst possible value).

  8. Length of Stay in the Hospital

    Time frame: Until discharge from hospital (up to day 90)

    Length of stay was analysed in two approaches. First, it was calculated and analysed only for patients who did not die before end of study of the individual patient. As a sensitivity analysis, the analysis was carried out including patients who died with the maximum possible length of stay (i.e., the worst possible value).

  9. Area Under the Curve (AUC) of Sepsis-related Organ Failure Assessment (SOFA) Score Per Day From Screening to Day 4

    Time frame: From Screening to Day 4

    The Sepsis-related Organ Failure Assessment (SOFA) score in this study is reported for entire days, not for exact time points on a day. Potentially, more than one SOFA score may be available for the same day. In this case, the mean of the respective total scores was used for that day for calculation of Area Under the Curve (AUC).

    The SOFA score includes sub-scores for Respiration, Coagulation, Liver, Cardiovascular, Central Nervous System and Renal function and may range from 0 (worst outcome) to 4 (best outcome).

Other outcomes

  1. Mortality

    Time frame: From Screening to end of Follow-up

    Mortality was reported for the time period from Screening until the end of follow-up.

  2. Changes in Renal Function: 1. Acute Renal Failure (ARF) at Any Time After Screening

    Time frame: From screening to end of follow-up (up to day 90)

    Acute Renal Failure (ARF) was defined as a two fold increase in serum concentration over the value at screening at any time after screening.

  3. Changes in Renal Function: 2. Acute Kidney Injury Network (AKIN) Classification

    Time frame: From screening to end of follow-up

    Acute Kidney Injury Network (AKIN) Classification in this study is based on serum creatinine values and renal replacement therapy, i.e. ignoring criteria based on urine output, as fulfilment of urine output criteria cannot be determined from the data collected in the study. AKIN ranges from stage 1 to stage 3 (worst outcome). Stages differ in serum creatinine increase. Stage 1: Increase ≥ 0.3mg/dL or ≥ 150%-200% from reference; Stage 2: Increase ≥ 200%-300% from reference; Stage 3: Increase >300% from reference with an acute increase of at least 0.5mg/dL or renal replacement therapy.

  4. Changes in Renal Function: 3. Risk, Injury, Failure, Loss, End-stage Kidney Disease (RIFLE) Classification

    Time frame: From screening to end of follow-up

    Risk, Injury, Failure, Loss, End-stage kidney disease (RIFLE) Classification in this study is based on serum creatinine values and renal replacement therapy, i.e. ignoring criteria based on urine output, as fulfilment of urine output criteria cannot be determined from the data collected in the study.

    RIFLE comprises five categories: Risk (R), Injury (I), Failure (F), Loss (L), End-stage kidney disease (E) (worst outcome). R, I and F are based on increase in serum creatinine. L and E are based on administration of renal replacement therapy.

Sponsors and collaborators

Lead sponsor

Fresenius Kabi

Industry

Registry information

Acronym: CRYSTMAS

Important dates

Study start
2007
Primary completion
2010
Study completion
2010
First posted
Apr 23, 2007
Registry last updated
Jan 11, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.